News stories about Sangamo Therapeutics (NASDAQ:SGMO) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sangamo Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.8636290809854 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- BidaskClub Downgrades Sangamo Therapeutics (SGMO) to Hold (americanbankingnews.com)
- Review of Price Trends: Sangamo Therapeutics, Inc. (SGMO) stock price concludes at $19.45 with move of 2.37% (nasdaqexpress.com)
- UNC-CH treats patient with novel genome-editing therapy (wraltechwire.com)
- Important Factors to Analyse A Good Investment – Sangamo Therapeutics, Inc. (NASDAQ: SGMO) (wallstreetnews24.com)
- Sangamo Therapeutics, Inc., (NASDAQ: SGMO) – Technical Indicators under Consideration (stocksnewstimes.com)
A number of equities research analysts recently commented on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Piper Jaffray set a $25.00 price objective on shares of Sangamo Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Wedbush restated a “neutral” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a report on Monday, February 12th. Finally, Jefferies Group restated a “buy” rating on shares of Sangamo Therapeutics in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $20.83.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. During the same period in the prior year, the firm posted ($0.14) EPS. The company’s revenue was up 46.6% on a year-over-year basis. analysts expect that Sangamo Therapeutics will post -0.15 earnings per share for the current fiscal year.
In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $17.26, for a total value of $258,900.00. Following the completion of the sale, the vice president now owns 13,015 shares of the company’s stock, valued at $224,638.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kathy Yi sold 5,000 shares of the stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $25.56, for a total transaction of $127,800.00. Following the completion of the sale, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at approximately $313,110. The disclosure for this sale can be found here. Insiders sold 95,403 shares of company stock worth $2,035,169 in the last 90 days. 5.50% of the stock is currently owned by insiders.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.